Brian A. Van Tine, MD, PhD, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.
Brian A. Van Tine, MD, PhD, associate professor, Department of Medicine, director, Sarcoma Program, Division of Medical Oncology, Washington University School of Medicine in St. Louis, and a medical oncologist, Siteman Cancer Center, discusses next steps with catequentinib (Anlotinib) in soft tissue sarcoma.
Findings from the phase 3 APROMISS trial (NCT03016819) demonstrated a progression-free survival advantage with catequentinib vs dacarbazine in patients with advanced or metastatic synovial sarcoma.
In the future, results from a non-randomized part of the study examining catequentinib in patients with alveolar soft tissue sarcoma, as well as the randomized part of the study evaluating catequentinib vs placebo in patients with leiomyosarcoma, will be presented, Van Tine explains. If both portions of the study lend positive results, catequentinib may be on track to receive FDA approval in soft tissue sarcoma, Van Tine adds.
Additionally, clinical trials may evaluate catequentinib in combination with other agents to increase efficacy, prolong durability of responses, and enhance response rates, Van Tine concludes.